Tobi (tobramycin inhalation solution, USP) 300mg/5mL
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
Geriatric Use - new section added
- added ..... bronchospasm and hearing loss.
- cross-references to the “WARNINGS – Ototoxicity” and “WARNINGS – Bronchospasm” sections have been added